Fasting-Mimicking Diet Regimen for IBD Pathology Reversal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current microbiome and probiotic-based therapies for gastrointestinal autoimmune/inflammatory diseases, such as Crohn's disease and ulcerative colitis, require refinement to effectively treat patients, as they often fail to provide sustained therapeutic effects and adequate reversal of IBD pathology.
Innovation Solution
A method combining a fasting-mimicking diet (FMD) with refeeding cycles to enhance the cultivation and expansion of beneficial gut microbiota, using a probiotic composition including Lactobacilluseae, Erysipelotrichaceae, and Bifidobacteriaceae, along with prebiotic ingredients, to promote therapeutic effects against gastrointestinal autoimmune and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If water-only fasting cycles are used, then some therapeutic effects are achieved, but the reversal of IBD pathology is insufficient and beneficial microbiota expansion is limited
Solution Approach 1:
The patent transforms the fasting regime from complete starvation (water-only) to a controlled nutritional state by introducing specific macronutrient compositions (low carbohydrate, moderate protein, high fat) during the fasting-mimicking diet period. This parameter change in dietary composition enables both therapeutic effects and enhanced microbiota expansion without the harmful effects of complete fasting.
Solution Approach 2:
The patent creates a composite dietary approach combining elements of fasting (caloric restriction) with specific nutritional components (healthy fats, proteins, prebiotics) that work synergistically. The FMD composition acts as a composite intervention that mimics fasting benefits while providing selective nutrients to cultivate beneficial microbiota, thereby improving both therapeutic reliability and pathology reversal productivity.
2Reliability
If traditional probiotic therapies are administered, then some beneficial effects are observed, but sustained therapeutic effects and adequate reversal of IBD pathology are not achieved
Solution Approach 1:
The patent implements a cyclic regimen alternating between fasting-mimicking diet periods (5 days) and refeeding periods (2 days), creating periodic nutritional stress that promotes sustained microbiota changes. This periodic action prevents adaptation and maintains therapeutic effects over time, addressing the limitation of continuous probiotic administration that fails to provide sustained benefits.
Solution Approach 2:
The FMD protocol performs preliminary cultivation of beneficial microbiota through controlled nutritional conditioning before full refeeding occurs. This preliminary action during the 5-day FMD phase prepares the gut environment to receive and sustain probiotic strains more effectively, extending the duration of therapeutic effects beyond what traditional continuous probiotic therapy achieves.
3Object-affected harmful factors
If complete fasting is implemented, then inflammation reduction may occur, but intestinal regeneration and microbiota expansion are insufficient
Solution Approach 1:
The patent applies local quality by providing selective nutritional support during FMD that specifically targets gut microbiota cultivation while maintaining systemic caloric restriction. The high fat and protein content with prebiotics in the FMD composition creates a localized favorable environment for beneficial microbiota in the gut, while the overall caloric deficit continues to reduce systemic inflammation.
Solution Approach 2:
The FMD composition acts as an intermediary substance that mediates between the opposing requirements of inflammation reduction (needing caloric restriction) and microbiota expansion (needing nutritional substrates). By providing specific macronutrients in controlled amounts, the FMD serves as a bridge that enables both anti-inflammatory effects and microbiota proliferation simultaneously.
Data Source
AI summary
A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. The fasting mimicking diet provides the subject with at most 50% to 75% of the subject's normal caloric intake. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.